Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 92

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 92
---
 our patent protection. For example, the federal courts of the U.S. have taken an increasingly dim view of the patent
eligibility of certain subject matter, such as naturally occurring nucleic acid sequences, amino acid sequences and certain methods of
utilizing the same, which include their detection in a biological sample and diagnostic conclusions arising from their detection. Such
subject matter, which had long been a staple of the biotechnology and biopharmaceutical industry to protect their discoveries, is now
considered, with few exceptions, ineligible in the first instance for protection under the patent laws of the U.S. Accordingly, we cannot
predict the breadth of claims that may be allowed and remain enforceable in our patents or in those licensed from a third party.

Even if our patent applications issue as patents,
they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise
provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar
or alternative technologies or products in a non-infringing manner.

We also may rely on the regulatory period of market
exclusivity for any of our biologic product candidates that are successfully developed and approved for commercialization. Although this
period in the United States is generally 12 years from the date of marketing approval (depending on the nature of the specific product),
there is a risk that the U.S. Congress could amend laws to significantly shorten this exclusivity period. Once any regulatory period of
exclusivity expires, depending on the status of our patent coverage and the nature of the product, we may not be able to prevent others
from marketing products that are biosimilar to or interchangeable with our products, which would materially adversely affect our business.

We depend on our licensors to maintain and enforce the intellectual property covering certain of our product candidates. We have limited, if any, control over the resources that our licensors can or will devote to securing, maintaining, and enforcing patents protecting our product candidates.

We depend on our licensors to protect the proprietary
rights covering our product candidates and we have limited, if any, control over the amount or timing of resources that they devote
on our behalf, or the priority they place on, maintaining patent rights and prosecuting patent applications to our advantage. Moreover,
we have limited, if any, control over the strategies and arguments employed in the maintenance of patent rights and the prosecution of
patent applications to our advantage. Our licensors might become involved in disputes with one